Foresee Pharmaceuticals Co., Ltd. (TPEX:6576)

Market Cap	12.23B -1.9%
Revenue (ttm)	471.13M +6.4%
Net Income	22.50M
EPS	0.14
Shares Out	157.54M
PE Ratio	543.44
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	71,570
Open	77.20
Previous Close	77.20
Day's Range	77.10 - 79.70
52-Week Range	71.90 - 93.70
Beta	0.57
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 12, 2026

About Foresee Pharmaceuticals

Foresee Pharmaceuticals Co., Ltd. operates as biopharmaceutical company in the United States, China, and Europe. The company’s stabilized injectable formulation pipeline includes FP-001, which completed Phase III clinical study for the treatment of advanced stage prostate cancer; FP-004 that is in preclinical stage to treat opioids use disorder; FP-011 and FP-014, a long-acting sustained release dosage form for the treatment of breast cancer/prostate cancer; and FP-016 for the treatment of neurological diseases. Its new chemical entity pipeline...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2013
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6576

Financial Performance

In 2025, Foresee Pharmaceuticals's revenue was 431.27 million, an increase of 3.01% compared to the previous year's 418.69 million. Losses were -883.15 million, -18.31% less than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 16, 2026

Data Sources Report a data error